Abstract
The 'omics' technologies represent analytical approaches that have a holistic view on molecules such as genes, transcripts, proteins and metabolites constituting a cell, tissue or organism. The profiling of genes, transcripts and proteins has been referred to as genomics, transcriptomics and proteomics. Finally, there is the youngest and most rapidly increasing of the “omics” disciplines: metabolomics. Metabolomics appears to be a new, very useful tool in neonatology, especially in the fields of pharma-metabolomics and nutri- metabolomics. Since it appears to be predictive and preventive, it can be considered the ‘new clinical chemistry’ for personalized neonatal medicine. At present, the use of metabolomics in neonatology is still in the pioneering phase. In clinical practice, only a limited number of metabolites are routinely measured in the biofluids of newborns by conventional analytical methods to study the metabolic status of the organism. However, the management of sick or preterm newborns might be improved if more information on perinatal/ neonatal maturational processes and their metabolic background were available.
The aim of this review, after a general introduction on pharma-metabolomics, is to present the potential of NMR-based metabolomic analysis of newbom urine in neonatology in the field of pharmacology.
Keywords: Metabolomics, newborn, drugs, therapy, genes, transcripts, proteins, neonatology, biofluids, pharmacology
Current Pharmaceutical Design
Title:Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Volume: 18 Issue: 21
Author(s): Vassilios Fanos, Luigi Barberini, Roberto Antonucci and Luigi Atzori
Affiliation:
Keywords: Metabolomics, newborn, drugs, therapy, genes, transcripts, proteins, neonatology, biofluids, pharmacology
Abstract: The 'omics' technologies represent analytical approaches that have a holistic view on molecules such as genes, transcripts, proteins and metabolites constituting a cell, tissue or organism. The profiling of genes, transcripts and proteins has been referred to as genomics, transcriptomics and proteomics. Finally, there is the youngest and most rapidly increasing of the “omics” disciplines: metabolomics. Metabolomics appears to be a new, very useful tool in neonatology, especially in the fields of pharma-metabolomics and nutri- metabolomics. Since it appears to be predictive and preventive, it can be considered the ‘new clinical chemistry’ for personalized neonatal medicine. At present, the use of metabolomics in neonatology is still in the pioneering phase. In clinical practice, only a limited number of metabolites are routinely measured in the biofluids of newborns by conventional analytical methods to study the metabolic status of the organism. However, the management of sick or preterm newborns might be improved if more information on perinatal/ neonatal maturational processes and their metabolic background were available.
The aim of this review, after a general introduction on pharma-metabolomics, is to present the potential of NMR-based metabolomic analysis of newbom urine in neonatology in the field of pharmacology.
Export Options
About this article
Cite this article as:
Fanos Vassilios, Barberini Luigi, Antonucci Roberto and Atzori Luigi, Pharma-metabolomics in Neonatology: is it a Dream or a Fact?, Current Pharmaceutical Design 2012; 18 (21) . https://dx.doi.org/10.2174/1381612811209022996
DOI https://dx.doi.org/10.2174/1381612811209022996 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lead Generation for Human Mitotic Kinesin Eg5 Using Structure-based Virtual Screening and Validation by In-vitro and Cell-based Assays
Current Computer-Aided Drug Design Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Sources of β-Cells for Cell Therapy in Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma
Current Cancer Drug Targets A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets HIV-1 Vpr: A Closer Look at the Multifunctional Protein from the Structural Perspective
Current HIV Research Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Current Medicinal Chemistry Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry Gene Modified Cell Transplantation for Vascular Regeneration
Current Gene Therapy Specificity of Binding in Protein Kinases
Current Enzyme Inhibition Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients
Cardiovascular & Hematological Disorders-Drug Targets Characterisation of Small Supernumerary Marker Chromosomes (sSMC) in Human
Current Genomics Epigenetics and Adult Acute Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Endocannabinoid System: A Promising Therapeutic Target for the Treatment of Haematological Malignancies?
Current Medicinal Chemistry Developmental Immunotoxicity (DIT) in Drug Safety Testing: Matching DIT Testing to Adverse Outcomes and Childhood Disease Risk
Current Drug Safety Cancer Stem Cells – Are Surface Markers Alone Sufficient?
Current Stem Cell Research & Therapy 2-Aminoimidazole, Glycociamidine and 2-Thiohydantoin-Marine Alkaloids as Molecular Inspirations for the Development of Lead Structures
Current Drug Targets Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design